New combo therapy shows promise for untreatable liver cancer

NCT ID NCT07610551

Recruiting now Disease control Sponsor: Air Force Military Medical University, China Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a combination of three treatments—radioactive beads (SIRT-Y90), an immunotherapy drug (atezolizumab), and a drug that cuts off tumor blood supply (bevacizumab)—for people with advanced liver cancer that cannot be surgically removed. Researchers will track how well the tumors shrink and how long patients live, using data from about 50 participants across eight hospitals in China. The goal is to see if this triple approach is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SIRT-Y90 (radioactive beads), atezolizumab (immunotherapy), bevacizumab (anti-angiogenic drug)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced liver cancer that cannot be removed by surgery, potentially shrinking tumors and extending life.
What could go wrong: This is a small, early-stage study with only 50 participants, so results may not apply to everyone. Combining these treatments may also increase side effects like liver damage or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

No. 777, Xitai Road, Chang'an District, Xi'an City, Shaanxi Province, China
RECRUITING

Xi’an, Shanxi, 710000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.